Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ECYT Endocyte	$23.99	$0.00	$2.81 ▼ $24.00	$1.97B	-0.01	2.12 million shs	N/A
JAZZ Jazz Pharmaceuticals	$110.32 +1.9%	$108.95	$95.49 ▼ $148.06	$6.80B	0.38	839,524 shs	702,054 shs
PRGO Perrigo	$26.51 -0.8%	$26.06	$23.14 ▼ $30.93	$3.64B	0.45	1.50 million shs	1.29 million shs
SUPN Supernus Pharmaceuticals	$32.23 +1.0%	$31.93	$25.53 ▼ $40.28	$1.80B	0.74	482,397 shs	499,581 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ECYT Endocyte	0.00%	0.00%	0.00%	0.00%	0.00%
JAZZ Jazz Pharmaceuticals	+0.01%	+0.20%	-9.80%	-22.07%	+2.89%
PRGO Perrigo	-0.38%	+0.71%	+4.12%	-9.05%	-2.99%
SUPN Supernus Pharmaceuticals	+0.38%	-0.59%	-2.83%	+0.82%	+17.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ECYT Endocyte	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	4.8912 of 5 stars	4.5	1.0	0.0	4.0	2.1	3.3	3.1
PRGO Perrigo	4.8268 of 5 stars	2.1	5.0	4.2	3.5	2.6	2.5	2.5
SUPN Supernus Pharmaceuticals	2.2305 of 5 stars	2.2	1.0	0.0	4.1	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ECYT Endocyte	0.00	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$182.93	65.82% Upside
PRGO Perrigo	2.25	Hold	$33.00	24.49% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	11.70% Upside

Current Analyst Ratings Breakdown

Latest ECYT, JAZZ, PRGO, and SUPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
4/10/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$210.00 ➝ $210.00
3/10/2025	JAZZ Jazz Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$200.00 ➝ $217.00
3/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$175.00 ➝ $183.00
3/7/2025	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$145.00 ➝ $179.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ECYT Endocyte	$70K	28,133.42	N/A	N/A	$1.99 per share	12.06
JAZZ Jazz Pharmaceuticals	$4.06B	1.67	$22.47 per share	4.91	$59.36 per share	1.86
PRGO Perrigo	$4.34B	0.84	$5.53 per share	4.79	$35.19 per share	0.75
SUPN Supernus Pharmaceuticals	$668.00M	2.70	$1.48 per share	21.83	$16.87 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ECYT Endocyte	-$55.06M	-$1.00	N/A	N/A	N/A	-32,296.09%	-21.19%	-20.55%	N/A
JAZZ Jazz Pharmaceuticals	$414.83M	$7.50	15.54	5.90	1.04	11.60%	29.30%	9.72%	7/30/2025 (Estimated)
PRGO Perrigo	-$12.70M	-$1.31	N/A	8.66	N/A	-3.64%	7.38%	3.18%	8/1/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$1.32M	$1.11	30.12	22.38	N/A	9.16%	7.79%	5.67%	8/5/2025 (Estimated)

Latest ECYT, JAZZ, PRGO, and SUPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ECYT Endocyte	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.38%	+4.77%	N/A	23 Years
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest ECYT, JAZZ, PRGO, and SUPN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ECYT Endocyte	N/A	45.80	45.80
JAZZ Jazz Pharmaceuticals	1.46	4.26	3.74
PRGO Perrigo	0.94	2.56	1.77
SUPN Supernus Pharmaceuticals	N/A	2.20	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ECYT Endocyte	75.62%
JAZZ Jazz Pharmaceuticals	89.14%
PRGO Perrigo	95.91%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ECYT Endocyte	10.65%
JAZZ Jazz Pharmaceuticals	4.20%
PRGO Perrigo	0.70%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ECYT Endocyte	N/A	82.09 million	N/A	Optionable
JAZZ Jazz Pharmaceuticals	3,200	61.65 million	57.92 million	Optionable
PRGO Perrigo	8,900	137.48 million	135.47 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	50.08 million	Optionable

ECYT, JAZZ, PRGO, and SUPN Headlines

Recent News About These Companies

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

June 2 at 5:37 AM | msn.com

Jefferies Financial Group Inc. Buys Shares of 24,600 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 31 at 4:35 AM | marketbeat.com

Voloridge Investment Management LLC Cuts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 31 at 4:10 AM | marketbeat.com

Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree

May 29, 2025 | quiverquant.com

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 29, 2025 | globenewswire.com

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025 | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), 908 Devices (MASS) and Supernus Pharmaceuticals (SUPN)

May 24, 2025 | theglobeandmail.com

Woodline Partners LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 24, 2025 | marketbeat.com

Point72 Asset Management L.P. Buys Shares of 26,828 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 24, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Deutsche Bank AG

May 22, 2025 | marketbeat.com

Supernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHD

May 20, 2025 | quiverquant.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Systematic Financial Management LP

May 20, 2025 | marketbeat.com

Captrust Financial Advisors Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 20, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Ameriprise Financial Inc.

May 19, 2025 | marketbeat.com

Jefferies Financial Group Inc. Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 18, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Polar Capital Holdings Plc

May 17, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Has $19.73 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 15, 2025 | marketbeat.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

May 14, 2025 | zacks.com

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 103,501 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 14, 2025 | marketbeat.com

Centiva Capital LP Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECYT, JAZZ, PRGO, and SUPN Company Descriptions

Endocyte NASDAQ:ECYT

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Jazz Pharmaceuticals NASDAQ:JAZZ

$110.32 +2.03 (+1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$110.36 +0.04 (+0.04%)

As of 06:23 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Perrigo NYSE:PRGO

$26.51 -0.20 (-0.76%)

Closing price 03:59 PM Eastern

Extended Trading

$26.52 +0.01 (+0.03%)

As of 04:40 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Supernus Pharmaceuticals NASDAQ:SUPN

$32.23 +0.32 (+1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$32.22 -0.01 (-0.02%)

As of 06:31 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time